drugset / Trial / NCT04054024
Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia
RandomizedParallel-groupDouble-blindTreatment
Summary
A placebo-controlled, double-blind, randomized proof-of-concept study to evaluate the efficacy and tolerability of the CGRP receptor antibody erenumab in treating pain experienced by subjects with TN.
Timeline
- Start
- 2019-10-28
- Primary completion
- 2021-10
- Completion
- 2021-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Erenumab | Monoclonal antibody | 140 mg | — |